Literature DB >> 7832225

Local therapy of corneal allograft rejection with cyclosporine.

J C Zhao1, X Y Jin.   

Abstract

PURPOSE: We evaluated the therapeutic effect of 0.5% topical cyclosporine on human corneal allograft rejection.
METHODS: Sixteen patients (16 eyes) with corneal allograft rejection, refractory to the conventional treatments, were recruited and treated with 0.5% cyclosporine eyedrops in this study.
RESULTS: Of 16 eyes with corneal graft rejection after penetrating keratoplasty treated with 0.5% cyclosporine eyedrops, nine eyes were completely cured, six eyes improved markedly, and treatment was ineffective in one eye. A follow-up of 12 to 24 months (three eyes for 12 months, five eyes for 18 months, and eight eyes for 24 months) disclosed that rejection recurred in three of the nine cured eyes--two eyes after suspension of cyclosporine and one eye after removal of the sutures. The recurrence of rejection resolved by resumption of the cyclosporine eyedrops.
CONCLUSIONS: This study demonstrated that treatment of corneal graft rejection with 0.5% topical cyclosporine yielded good results in eyes with satisfactory preoperative corneal transplantation beds and beneficial effects in eyes with poor preoperative corneal transplantation beds.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7832225     DOI: 10.1016/s0002-9394(14)73872-3

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  Systemic cyclosporin A in high failure risk, repeated corneal transplantation.

Authors:  S Rumelt; V Bersudsky; T Blum-Hareuveni; U Rehany
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

2.  Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A.

Authors:  P Calvo; A Sanchez; J Martinez; M I Lopez; M Calonge; J C Pastor; M J Alonso
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

Review 3.  Literature review and suggested protocol for prevention and treatment of corneal graft rejection.

Authors:  Otavio Azevedo Magalhaes; Ahmed Shalaby Bardan; Mehran Zarei-Ghanavati; Christopher Liu
Journal:  Eye (Lond)       Date:  2019-07-22       Impact factor: 3.775

Review 4.  Management of high-risk corneal transplantation.

Authors:  Antonio Di Zazzo; Ahmad Kheirkhah; Tulio B Abud; Sunali Goyal; Reza Dana
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

5.  Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial.

Authors:  Rajesh Sinha; Vishal Jhanji; Kamna Verma; Namrata Sharma; Nihar R Biswas; Rasik B Vajpayee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-23       Impact factor: 3.117

6.  The Effect of Topical 0.05% Cyclosporine in the Prevention of Recurrence Following Pterygium Surgery.

Authors:  Ayse Sevgi Karadag; Emre Guler; Emre Guler
Journal:  Beyoglu Eye J       Date:  2021-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.